Free Trial
Your Portfolio Deserves Better! MarketBeat All Access for Just $149
Upgrade Now
Claim MarketBeat All Access Sale Promotion

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$22.60
+1.4%
$23.92
$13.74
$70.43
$5.14B2.4332.88 million shs16.65 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,012.78
+2.5%
$940.00
$623.78
$1,133.95
$954.77B0.483.17 million shs1.55 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$44.60
+0.7%
$39.84
$35.12
$81.44
$199.17B0.7721.51 million shs4.98 million shs
10 Stocks Set to Soar in 2026 Cover

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
-11.22%-23.58%-22.56%+36.44%-65.47%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-1.64%+2.37%+6.67%-4.54%+30.58%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
-0.87%-4.35%+9.50%-10.10%-31.12%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$22.60
+1.4%
$23.92
$13.74
$70.43
$5.14B2.4332.88 million shs16.65 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,012.78
+2.5%
$940.00
$623.78
$1,133.95
$954.77B0.483.17 million shs1.55 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$44.60
+0.7%
$39.84
$35.12
$81.44
$199.17B0.7721.51 million shs4.98 million shs
10 Stocks Set to Soar in 2026 Cover

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
-11.22%-23.58%-22.56%+36.44%-65.47%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-1.64%+2.37%+6.67%-4.54%+30.58%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
-0.87%-4.35%+9.50%-10.10%-31.12%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
2.12
Hold$29.5033.27% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.87
Moderate Buy$1,218.3319.53% Upside
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
2.13
Hold$65.5646.98% Upside

Current Analyst Ratings Breakdown

Latest NVO, LLY, and HIMS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/13/2026
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Lower Price TargetNeutral$32.00 ➝ $30.00
5/12/2026
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
DowngradeHold (C)Sell (D)
5/12/2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Reiterated RatingNeutral
5/12/2026
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Set Price Target$24.50
5/12/2026
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Set Price Target$35.00
5/12/2026
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Set Price Target$32.00
5/12/2026
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Boost Price TargetNeutral$24.00 ➝ $28.00
5/12/2026
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Lower Price TargetOverweight$35.00 ➝ $33.00
5/12/2026
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Boost Price TargetBuy$30.00 ➝ $35.00
5/12/2026
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Reiterated RatingNeutral
5/7/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price Target$880.00 ➝ $900.00
(Data available from 5/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$2.35B2.15$0.74 per share29.93$2.38 per share9.30
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$72.25B13.29$25.49 per share39.98$28.07 per share36.31
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$46.80B4.26$4.68 per share9.54$6.58 per share6.78
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$128.37M-$0.09N/A45.1744.19-0.56%6.10%1.52%N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$20.64B$28.1536.2223.041.0934.98%105.77%23.76%8/5/2026 (Estimated)
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$15.51B$4.2610.5112.973.9837.23%63.31%22.19%8/5/2026 (Estimated)

Latest NVO, LLY, and HIMS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/11/2026Q1 2026
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$0.04-$0.40-$0.44-$0.40$616.84 million$608.10 million
5/6/2026Q1 2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.87$1.04+$0.17$1.69$10.86 billion$10.85 billion
4/30/2026Q1 2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.97$8.55+$1.58$8.26$17.82 billion$19.80 billion
3/31/2026Q1 2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
N/A$1.0270N/A$1.69N/A$10.85 billion
2/23/2026Q4 2025
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$0.02$0.08+$0.06$0.08$619.48 million$617.82 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
N/AN/AN/AN/AN/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.920.68%+15.18%24.58%11 Years
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$1.753.92%+21.74%41.08%N/A

Latest NVO, LLY, and HIMS Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/4/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.730.69%5/15/20265/15/20266/10/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
2.18
1.69
1.56
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.26
1.50
1.10
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.59
0.79
0.56

Institutional Ownership

CompanyInstitutional Ownership
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
63.52%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
11.54%

Insider Ownership

CompanyInsider Ownership
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
11.76%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.14%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.07%
CompanyEmployeesShares OutstandingFree FloatOptionable
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
2,442227.94 million201.13 millionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
50,000941.74 million940.42 millionOptionable
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
69,5054.47 billion4.46 billionOptionable

Recent News About These Companies

Three Biotechs That Are Top Takeover Targets
Three Biotechs That Are Top Takeover Targets
Novo Nordisk A/S - share repurchase programme
Novo Nordisk A/S (NYSE:NVO) Stock Rating Upgraded by Wall Street Zen
Novo Nordisk A/S (NYSE:NVO) Upgraded at Wall Street Zen
Buy, Sell, or Hold Novo Nordisk at $46?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Hims & Hers Health stock logo

Hims & Hers Health NYSE:HIMS

$22.60 +0.31 (+1.37%)
As of 01:22 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$1,012.78 +24.69 (+2.50%)
As of 01:22 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Novo Nordisk A/S stock logo

Novo Nordisk A/S NYSE:NVO

$44.60 +0.32 (+0.71%)
As of 01:22 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.